We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+2.35%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$7.71B
AUM Growth
-$201M
(-2.5%)
Cap. Flow
-$473M
Cap. Flow
% of AUM
-6.14%
Top 10 Holdings %
Top 10 Hldgs %
39.08%
Holding
169
New
28
Increased
15
Reduced
34
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nautilus Biotechnolgy
NAUT
|
+$96.5M |
| 2 |
United Therapeutics
UTHR
|
+$84.1M |
| 3 |
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
|
+$79.6M |
| 4 |
ZY
Zymergen Inc. Common Stock
ZY
|
+$64.5M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$60M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$46.3M |
| 2 |
Allogene Therapeutics
ALLO
|
+$40.4M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$39.9M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$36.4M |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$35.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.76% |
| 2 | Miscellaneous | 11.22% |
| 3 | Financials | 0.64% |
| 4 | Consumer Staples | 0.2% |
| 5 | Industrials | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Health Catalyst
HCAT
$129M
| $31.4M | 0.41% |
566,084
+60,000
| +12% | +$3.2M |
|
52
Xenon Pharmaceuticals
XENE
$5.45B
| $31.3M | 0.41% |
1,678,973
+1,163,931
| +226% | +$21.5M |
|
|
DRNA
53
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $29.9M | 0.39% |
800,000
| – | – |
|
|
BCAB
54
DELISTED
BIOATLA INC
BCAB
| $29.1M | 0.38% |
+13,710
| New | +$31M |
|
|
EXAS
55
DELISTED
Exact Sciences
EXAS
| $29M | 0.38% |
233,523
-120,000
| -34% | -$14.3M |
|
56
Immatics
IMTX
$1.31B
| $29M | 0.38% |
2,500,000
| – | – |
|
|
NARI
57
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $29M | 0.38% |
310,437
-254,676
| -45% | -$24.7M |
|
|
ISEE
58
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $28.9M | 0.38% |
4,585,512
| – | – |
|
|
XLRN
59
DELISTED
Acceleron Pharma
XLRN
| $28.5M | 0.37% |
+226,760
| New | +$28.6M |
|
60
Nuvation Bio
NUVB
$2.04B
| $28.3M | 0.37% |
3,041,004
| – | – |
|
61
Alphatec Holdings
ATEC
$1.65B
| $27.6M | 0.36% |
1,800,180
| – | – |
|
62
Travere Therapeutics
TVTX
$5.89B
| $26.9M | 0.35% |
1,845,555
-1,452,864
| -44% | -$28.7M |
|
|
LENZ
63
LENZ Therapeutics
LENZ
$133M
| $26.9M | 0.35% |
+125,013
| New | +$21.8M |
|
|
RNAM
64
DELISTED
Avidity Biosciences
RNAM
| $26.7M | 0.35% |
1,079,028
-20,000
| -2% | -$465K |
|
65
Kodiak Sciences
KOD
$2.07B
| $26.6M | 0.35% |
286,041
-102,967
| -26% | -$9.88M |
|
66
ADMA Biologics
ADMA
$1.93B
| $26.5M | 0.34% |
16,584,802
| – | – |
|
67
Repligen
RGEN
$9.86B
| $26.4M | 0.34% |
+132,500
| New | +$25.7M |
|
68
Arrowhead Research
ARWR
$9.98B
| $26.1M | 0.34% |
315,141
-94,200
| -23% | -$7.01M |
|
|
LYRA
69
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $25.9M | 0.34% |
64,451
| – | – |
|
70
Cogent Biosciences
COGT
$5.68B
| $25.9M | 0.34% |
3,188,750
| – | – |
|
71
PMV Pharmaceuticals
PMVP
$72.7M
| $25.5M | 0.33% |
746,557
| – | – |
|
|
INBX
72
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $25M | 0.32% |
+907,090
| New | +$18.9M |
|
73
Celldex Therapeutics
CLDX
$3.02B
| $24.8M | 0.32% |
+742,699
| New | +$20.4M |
|
74
Collegium Pharmaceutical
COLL
$711M
| $23.1M | 0.3% |
978,277
| – | – |
|
|
FBRX
75
DELISTED
Forte Biosciences
FBRX
| $23M | 0.3% |
27,400
| – | – |
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2021 Portfolio in Review
As of Q2 2021, Perceptive Advisors held 169 positions worth $7.71B, down 2.5% from $7.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Perceptive Advisors withdrew a net $473M in Q2 2021, closing 19 positions and reducing 34 holdings. Its most notable exit was Allogene Therapeutics, an estimated $40.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Perceptive Advisors opened a new position in Nautilus Biotechnolgy worth $90M.
- Perceptive Advisors's largest Q2 2021 buy was Nautilus Biotechnolgy: 8,911,151 shares worth $90M.
- Perceptive Advisors added most to United Therapeutics in Q2 2021, an estimated $84.1M increase.
- Perceptive Advisors's biggest Q2 2021 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $46.3M.
- Perceptive Advisors fully exited Allogene Therapeutics in Q2 2021, selling an estimated $40.4M.
- Perceptive Advisors's ten largest holdings make up 39% of its $7.71B portfolio in Q2 2021.
- Perceptive Advisors opened 28 new positions and closed 19 in Q2 2021.
- Perceptive Advisors's portfolio value fell 2.5% quarter-over-quarter to $7.71B.
Based on Perceptive Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.